In relation to the systemic illnesses more prevalent in people with schizophrenia, recent reports of the presence of CHRM1 on the pancreas (Pacher et al., 2019) and as a suggested drug target for the treatment of gastrointestinal and liver diseases (Tolaymat et al., 2021) are of interest. Here, CHRM1 is linked to schizophrenia.